Employees: 11 (2023.0)Legal category: 5485Size: PMECreation date: 2009-06-10 (16 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: PONT-SAINT-ESPRIT (30130), Gard
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELARL PHARMACIE PARDON : revenue, balance sheet and financial ratios
SELARL PHARMACIE PARDON is a French company
founded 16 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in PONT-SAINT-ESPRIT (30130),
this company of category PME
shows in 2024 a net income positive of 90 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE PARDON (SIREN 513378117)
Indicator
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
89 673 €
68 005 €
-259 297 €
175 053 €
154 425 €
92 424 €
121 256 €
81 956 €
80 988 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2024, SELARL PHARMACIE PARDON generates positive net income of 90 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 81 k€ -> 90 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
89 673 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 160%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 33%. The balance between equity and debt is satisfactory.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
159.75%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
33.223%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Debt ratio
1123.368
744.471
482.246
348.159
257.913
184.978
254.384
197.201
159.75
Financial autonomy
7.25
10.315
14.948
18.436
24.272
29.797
24.283
29.131
33.223
Repayment capacity
None
None
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
159.752024
2022
2023
2024
Q1: 16.46
Med: 58.48
Q3: 154.77
Average
In 2024, the debt ratio of SELARL PHARMACIE PARDON (159.75) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
33.22%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Average+5 pts over 3 years
In 2024, the financial autonomy of SELARL PHARMACIE PARDON (33.2%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 100.15. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
84.843
99.607
77.742
62.689
93.044
108.135
155.349
111.389
100.15
Interest coverage
None
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
100.152024
2022
2023
2024
Q1: 129.46
Med: 182.14
Q3: 260.79
Watch-10 pts over 3 years
In 2024, the liquidity ratio of SELARL PHARMACIE PARDON (100.15) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
Positioning of SELARL PHARMACIE PARDON in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of SELARL PHARMACIE PARDON is estimated at
1 251 901 €
(range 871 804€ - 1 872 916€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
871k€1251k€1872k€
1 251 901 €Range: 871 804€ - 1 872 916€
NAF 5 année 2024
Valuation method used
Net Income Multiple
89 673 €
×
14.0x
=1 251 901 €
Range: 871 804€ - 1 872 916€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE PARDON with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE PARDON
What is the revenue of SELARL PHARMACIE PARDON ?
The revenue of SELARL PHARMACIE PARDON is not publicly disclosed (confidential accounts filed with INPI).
Is SELARL PHARMACIE PARDON profitable?
Yes, SELARL PHARMACIE PARDON generated a net profit of 90 k€ in 2024.
Where is the headquarters of SELARL PHARMACIE PARDON ?
The headquarters of SELARL PHARMACIE PARDON is located in PONT-SAINT-ESPRIT (30130), in the department Gard.
Where to find the tax return of SELARL PHARMACIE PARDON ?
The tax return of SELARL PHARMACIE PARDON is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE PARDON operate?
SELARL PHARMACIE PARDON operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart